ARA-290
Sourcing GuideProcurement-quality evaluation of ARA-290 centres on six markers: lot-specific COA availability, HPLC purity ≥98%, mass spec confirmation matching 1257 Da, endotoxin testing for injectable routes, vendor regulatory disclosure, and cold-chain shipping options. Selectively activates the innate repair receptor (β-common-receptor / EPOR heteromer) on injured tissue Reduces inflammatory cytokine release and supports nerve and tissue repair. Critically, it does not bind the homodimeric EPOR responsible for erythropoiesis.. The QC discipline applies regardless of the application; sourcing standards do not relax for any particular use case.
Key Takeaways
Procurement lens: ARA-290 sourcing requires lot-specific COA, HPLC purity ≥98%, mass spec confirmation matching 1257 Da. Mechanism: Selectively activates the innate repair receptor (β-common-receptor / EPOR heteromer) on injured tissue. Storage: lyophilised at -20°C for 18-24 months; reconstituted at 4°C for 14-28 days. Vendor tier: pharmaceutical-grade compounded > reputable research-grade > grey-market (3-5x cost differential; quality differential substantially larger). Sourcing-validated stack partners: BPC-157, TB-500, GHK-Cu.
Selectively activates the innate repair receptor (β-common-receptor / EPOR heteromer) on injured tissue. Reduces inflammatory cytokine release and supports nerve and tissue repair. Critically, it does not bind the homodimeric EPOR responsible for erythropoiesis. Sourcing implications: the mechanism dictates which analytical assays are appropriate for QC, which storage conditions preserve activity, and which reconstitution and use practices matter. The subsections below cover HPLC and analytical identity, COA evaluation and red flags, reconstitution and storage, and vendor tier comparison for ARA-290.
Vendor tier comparison and price discipline
Three vendor tiers operate in the ARA-290 market: pharmaceutical-grade compounded prescription (physician-supervised, full COA, ICP-MS where relevant, highest cost), reputable research-chemical vendors (full COA, lot-specific, mid-tier cost), and grey-market unverified sources (template or absent COA, unverifiable supply chain, lowest cost). The price differential between tiers is roughly 3–5x; the quality differential is substantially larger and concentrated in the bottom tier.
HPLC purity and analytical identity
Minimum acceptable HPLC purity for ARA-290 is ≥98% in research-grade material. Mass spec confirmation should show the characteristic m/z of 1257 (M+H)+. Contaminant peaks above 1% in the HPLC trace warrant quantification on the COA and — ideally — structural identification of the major impurities.
COA evaluation and red flags
Acceptable ARA-290 certificates of analysis specify: (1) lot number matching the vial, (2) HPLC purity with chromatographic trace, (3) mass spec confirmation, (4) endotoxin testing for SubQ-route use, and (5) issuance from an accredited third-party laboratory. Template COAs that cannot be traced to a specific lot, COAs missing endotoxin data for injectable material, and COAs issued by the vendor's own laboratory rather than a third party are all sourcing red flags.
Sourcing ARA-290 for lyophilisation quality use requires the same QC discipline as any peptide procurement: lot-specific COA, HPLC purity ≥98%, mass spec confirmation, endotoxin testing for injectable routes. Application-specific use does not relax the sourcing standard.
Pharmaceutical-grade compounded ARA-290 is the lowest-risk sourcing path for red flag detection use where the route permits, particularly for users with clinical supervision. Research-grade material from accredited vendors is the practical alternative; grey-market sourcing is not appropriate for this application.
For users targeting coa review, the sourcing question is whether the chosen vendor consistently delivers analytical-spec material across lots. Repeated re-orders from the same vendor with mid-cycle COA spot-checks is the procurement pattern that catches lot drift before it affects results.
Sourcing ARA-290 for mass spectrometry verification use requires the same QC discipline as any peptide procurement: lot-specific COA, HPLC purity ≥98%, mass spec confirmation, endotoxin testing for injectable routes. Application-specific use does not relax the sourcing standard.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | SubQ | 4 mg | 8–12 weeks on / 4 weeks off |
| Conservative starter | SubQ | 2 mg | 4–6 weeks initial cycle |
| Sourcing Guide focus | SubQ | 4 mg | 1x daily SubQ |
| Maintenance phase | SubQ | 3 mg | Ongoing with periodic pauses |
Dose timing for ARA-290 is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.
ARA-290 stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from experienced peptide buyers.
- ARA-290 + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with ARA-290's mechanism in sourcing / quality / procurement protocols.
- ARA-290 + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with ARA-290's mechanism in sourcing / quality / procurement protocols.
- ARA-290 + GHK-Cu: GHK chelates copper(II) and acts as a transcriptional modulator: published microarray data show it influences over 4,000 human genes including resetting expression patterns toward younger cellular phenotypes. Pairs naturally with ARA-290's mechanism in sourcing / quality / procurement protocols.
- ARA-290 + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with ARA-290's mechanism in sourcing / quality / procurement protocols.
Excellent tolerability in published trials. Does not raise hemoglobin. Watch for rare injection site reactions.
Lens-specific safety considerations for sourcing / quality / procurement use of ARA-290: Excellent tolerability in published trials. Does not raise hemoglobin. Watch for rare injection site reactions. Additional sourcing / quality / procurement monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| ARA-290 | EPO-derived tissue-protective peptide | ~2 min plasma; long tissue effect | Sourcing Guide |
| BPC-157 | Stable gastric pentadecapeptide | ~4 hr (oral) | Accelerated tendon, ligament, and gut tissue repair via VEGFR2-driven angiogenesis and FAK-paxillin signalling |
| TB-500 | Synthetic thymosin β4 fragment | ~2-3 days | A 17-amino-acid synthetic fragment of thymosin β4 with actin-sequestering activity — drives cell migration, tissue repair, and broad regenerative effects |
| GHK-Cu | Tripeptide-copper complex | ~30 min plasma | A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression |
| Ipamorelin | Selective GHRP / ghrelin mimetic | ~2 hr | The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite |
What should I check on a ARA-290 COA?
Storage protocol?
Reconstitution best practices?
Pharmaceutical-grade versus research-grade?
Is ARA-290 safe during pregnancy or breastfeeding?
How long until I see results from ARA-290?
Start a ARA-290 Protocol
Alukard provides GMP-certified physician-supervised sourcing with GMP-certified ARA-290 and Pharmaceutical-grade compounds with full COA documentation.
Get ProtocolQuick Facts
- Molecular weight
- 1257 Da
- Sequence length
- 11 aa
- Half-life
- ~2 min plasma; long tissue effect
- WADA
- Not specifically listed (EPO analogues require care)
- FDA
- Unapproved (Phase II/III in sarcoidosis & neuropathy)
- Research
- Multiple Phase II human trials
Stack Partners
All sourcing / quality / procurement applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for ARA-290 unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Sourcing / Quality / Procurement Protocol for ARA-290
Alukard provides GMP-certified physician-supervised sourcing with Pharmaceutical-grade compounds with full COA documentation.
HIPAA Compliant · GMP Certified · Physician Supervised